about us

our partners

The companies, charity and researchers Kode Biotech works with to take Kode Technology to market.

Kode Group licensees: KIE commercialisation companies

These three companies license Kode Technology to develop Kode Immunoeducers.

Spin-out company · human cancer

KodeRx

Develops K5K, a Gen 3 KIE, with a focus on affordable and accessible products.

Spin-out company · human cancer

Kode Agalimmune

Develops AGI-134, a Gen 2 KIE, and holds the alpha(Gal)OV-IO oncolytic virus asset.

Spin-out company · veterinary cancer

Kode Veterinary Sciences

Develops Kv9, a Gen 3 KIE, for veterinary cancer.

the full Kode Group

Kode Biotech partners: distribution and access

  • DistributionMerck MilliporeSigmaDistributes Kode FSL constructs and other glycoconjugates for research, worldwide (with exclusivity for the USA and Canada) through its catalogue.
  • Independent charity partnerEquitable Oncology is an independently governed New Zealand registered charity (CC64930) working to improve equitable access to cancer treatment. Its mission is to help more people access cancer treatment by advancing affordability and accessibility through collaboration, innovation and partnerships.

    Equitable Oncology operates independently, with its Board responsible for strategic direction and decision-making, including which programmes and partnerships to support and how resources are allocated in accordance with its charitable purpose.

    K5K, an investigational Gen 3 KIE developed by Kode Biotech, is the first programme selected to progress through the Equitable Oncology Model. KodeRx is the commercialisation company responsible for advancing K5K through clinical development and towards commercialisation.

    Equitable Oncology plays an active role in bringing together and coordinating the clinical, scientific, philanthropic and other partnerships needed to advance K5K, drawing on existing expertise, capabilities and resources rather than seeking to develop them all within one organisation.

    Affordability and accessibility have been central to K5K's development from the outset. The Equitable Oncology Model builds on this foundation, creating a pathway for clinical development and commercialisation that aims to minimise the costs ultimately passed on to patients and improve the affordability and accessibility of cancer treatment.

    equitableoncology.com
    Donate to Equitable Oncology

Kode Biotech partners: manufacturing, supply and licensees

Manufacturing partner

GlycoSyn

A New Zealand manufacturer that will make Kode Immunoeducers to clinical-grade (GMP) standard.

Manufacturing partner

Synpel Chemical

A Czech Republic chemical manufacturer that makes Kode FSL and GlycoNZ products.

Commercial licensee

Immulab

Manufactures and supplies Securacell, blood-bank quality controls made with Kode Technology. CSL launched Securacell in 2005.

Kode Technology research: a worldwide network

Kode Technology is continuously developed and tested with a worldwide network of research collaborators, including universities, blood services, and commercial and pharmaceutical organisations. Many of these collaborations are confidential, so we don't name them here. Published work is listed on Science and Publications.

science and publications propose a research collaboration →

Work with us: become a partner

Custom FSL constructs, research collaboration, Kode Immunoeducer and other licensing partnerships.